Objective:

To promote the long-term integration of precision medicine and care, transforming digital PGx outcomes into tangible health benefits for patients.

Approach:

• Methods: A structured narrative review was conducted, searching PubMed, Embase, and CINAHL for relevant literature from January 2010 to January 2026, focusing on guidelines, pragmatic trials, randomized controlled studies, meta-analyses, and implementation studies rela…

Key Findings:

• Current evidence supports PGx as an adjunctive prescribing tool for selected antidepressants and antipsychotics with established drug-gene guidance.
• Pooled estimates from depression trials suggest modest improvements in remission or response, but benefits vary significantly.
• Patients most likely to benefit from PGx testing include those with prior treatment failure, troublesome adverse effects, and complex polypharmacy.
• Routine testing for all psychiatric patients is not supported by current evidence.
• Nurses can play a crucial role in medication history-taking, patient education, and monitoring, but implementation requires attention to workforce capability and integration into electronic health records.

Interpretation:

PGx should be integrated into a broader precision-prescribing framework in psychiatry to enhance clinical practice.

Limitations:

• Implementation challenges due to limited structured genotype fields in electronic health records.
• Inconsistent interpretation of PGx reports and varying clinician awareness and acceptance.

Conclusion:

PGx has the potential to transform clinical practice in psychiatry, but requires careful integration into existing care pathways.